CDK4/6 Inhibitors Prevent Cancer Metastasis

Technology #2016-055

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Zhenkun Lou Ph.D.
Tongzheng Liu Ph.D.
Managed By
Leif R. Nelson
Patent Protection
US Patent Pending

Mayo Clinic has discovered the functional roles for DUB3, an ubiquitin specific protease, and CDK4/6 inhibitors, in their ability to regulate cancer metastasis. CDK4/6 inhibitors blocked triple-negative breast cancer metastasis.